New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
View original at globenewswire.comNew data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a novel sou…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
AI-Immunology™ is a unique platform for designing vaccines for many different cancer types, combining neoantigens with other types of antigens, which holds great potential for improving vaccine efficacy
60% confidenceAI-Immunology™ can be applied across a range of different cancers as well as other diseases
60% confidenceThere is a dire need for better treatment options for glioblastoma, which is refractory to immunotherapy due to low mutational burden and paucity of canonical neoantigens. ERVs constitute a new tumor-specific antigen source that can be targeted by vaccines alongside mutation-derived epitopes
60% confidenceIn addition to ERV-derived antigens, neoantigens of sufficient quality to include in a vaccine were identified in the majority of patients
60% confidenceERVs constitute a relevant antigen source that may overcome limitations imposed by low mutational burden, providing a strong Proof-of-Concept for personalized vaccines incorporating ERV-derived antigens
60% confidenceAI-Immunology™ has unique capabilities in identifying ERVs, opening a whole new source of antigens which can potentially greatly improve the efficacy of cancer vaccines for glioblastoma patients who generally have few neoantigens to target due to low mutational burden
60% confidenceERVs are tumor antigens from the dark genome that are present in tumors but absent in normal tissue, making them highly attractive targets for cancer vaccines
60% confidence